T-DM1 and Osimertinib (TRAEMOS) To Target HER2 Bypass Track Resistance in EGFRm plus NSCLC: Interim Analysis of a Phase II Trial

M. Jebbink, A. J. De Langen, K. Monkhorst, M. C. Boelens, D. Van den Broek, V. Van der Noort, C. J. De Gooijer, A. J. Van der Wekken, L. Hendriks, S. M. S. Hashemi, M. S. Paats, A. Dingemans, E. Smit

Research output: Contribution to journalMeeting AbstractAcademic

Original languageEnglish
Pages (from-to)S891-S892
JournalJournal of thoracic oncology
Issue number10
Publication statusPublished - Oct 2021


  • EGFR
  • HER2

Cite this